INTRODUCTION
Research in the past decade on glutamate receptors has provided a variety of new targets for pharmacological interventions. The family of metabotropic glutamate receptors (mGlu) comprises eight different receptor subtypes divided into three groups. These G-protein-linked receptors, which regulate production of second messengers and synaptic activity, control the release of multiple neurotransmitters and modulate neuronal excitability (Pin and Duvoisin, 1995; Schoepp, 2001) . The mGlu2/3 receptors belong to the group II metabotropic receptor family and when expressed are coupled to inhibition of adenylate cyclase and modulation of ion channels. Functionally, activation of mGlu2/3 receptors in vivo suppresses enhanced synaptic excitability via pre-and post-synaptic mechanisms (Schoepp, 2001) . These receptors are expressed primarily in forebrain regions, such as the amygdala and hippocampus, which are thought to play an important role in the expression of fear. Thus, they may also represent an important site of action for anxiolytic drugs, including mGlu2/3 receptor agonists (Swanson et al, 2005) .
LY354740, a glutamate analog, is a highly specific, nanomolar-potent agonist at mGlu2/3 receptors (Schoepp et al, 1997 (Schoepp et al, , 2003 . LY354740 has evidenced activity in a number of rodent stress and anxiety models, including fear-potentiated startle, elevated plus maze, lactate-induced panic, and stress-induced hyperthermia (Walker et al, 2002; Tizzano et al, 2002; Monn et al, 1997; Shekhar and Keim, 2000; Spooren et al, 2002) . Importantly, the effects of LY354740 occur at doses that are not associated with psychomotor impairment, which is common with benzodiazepine pharmacology (Helton et al, 1998; Tizzano et al, 2002) . Data in transgenic knockout mice lacking mGlu2 or mGlu3 receptors have shown that the anxiolytic actions of LY354740 in the elevated plus maze test require the expression of one or both mGlu2/3 receptors .
In two human models of anxiety, fear-potentiated startle and panic induction by CO 2 -challenge, LY354740 showed significant effects in decreasing anxiety compared with placebo in healthy volunteers and panic disorder patients, respectively (Grillon et al, 2003; Schoepp et al, 2003) . Anxiolytic activity was observed in initial, proof-of-concept studies in generalized anxiety disorder (GAD) (data on file, Eli Lilly and Co.) and in a large, multicenter, placebo and lorazepam-controlled GAD study (study LWAY; Michelson et al, 2005) . In this study, 738 DSM-IV GAD patients were randomized to receive LY354740 administered as 100 or 200 mg twice daily (b.i.d.) , placebo or lorazepam 4-5 mg daily, in a 3 : 3 : 3 : 2 ratio for up to 5 weeks of double-blind therapy. On the primary efficacy measure, the Hamilton Anxiety Scale (HAMA), both doses of LY354740 were associated with significantly greater efficacy than placebo and comparable to lorazepam 4-5 mg daily with a superior tolerability profile. Treatment effect sizes (and 95% confidence intervals (CIs)) were 0.29 (0.09, 0.48) and 0.21 (0.01, 0.41) for the LY354740 100 and 200 mg b.i.d. groups, respectively; for the lorazepam 4-5 mg daily group, it was 0.34 (0.12, 0.56 ). An exploratory analysis of the relationship between LY354740 plasma concentration and efficacy found an association between LY354740 plasma concentrations in the highest quartile and a higher rate of treatment response (defined as a decrease in HAMA total score from baseline X50%).
The estimated oral bioavailability of LY354740 in humans is only 3-5% due to limited gastrointestinal absorption limiting potential therapeutic applications. To improve LY354740 absorption and further assess the therapeutic effects of mGlu2/3 agonists, a pharmacologically inactive peptidyl prodrug (L-alanine) form of the active compound LY354740, named LY544344, was developed. LY544344 is absorbed in the gastrointestinal tract through active PEP T1 transport, with eventual hydrolysis to produce molar equivalents of LY354740 and L-alanine (Bueno et al, 2005; Rorick-Kehn et al, 2006) . In rodents, oral administration of LY544344 is associated with at least 10-fold improvement in bioavailability compared with oral LY354740 and behavioral effects comparable to those seen with parenteral administration of LY354740 (Rorick-Kehn et al, 2006) .
The findings reported in this paper are from the first efficacy study conducted with LY544344 in GAD. This study aimed to confirm that compounds that are agonists at the mGlu2/3 receptors can be associated with anxiolytic effects in clinical populations, as observed in previous studies with LY354740. The LY544344 doses selected for this study were expected to yield LY354740 plasma concentrations similar to those achieved in study LWAY (Michelson et al, 2005) .
MATERIALS AND METHODS

Study Design
The study was a randomized, double-blind, parallel, placebo-controlled, fixed dose comparison of LY544344 8 mg b.i.d., LY544344 16 mg b.i.d., and placebo conducted at 23 sites in seven countries in western Europe and originally intended to randomize up to approximately 672 patients with a diagnosis of GAD. Ethical Review Boards provided written approval of the study protocol and written informed consent was obtained from each patient before study enrollment. This study was conducted in accordance with applicable laws and regulations, Good Clinical Practices, and the Declaration of Helsinki. The protocol specified that primary objective of this clinical study was to assess the efficacy of LY544344 compared with placebo in the treatment of GAD, as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). The primary efficacy assessment was the analysis of mean change from baseline to last observation of the HAMA total score (Hamilton Anxiety Rating Score; Hamilton, 1959) during the 8-week, double-blind acute treatment phase.
Patients who met inclusion and exclusion criteria were randomly assigned to one of three treatment groups: 8 mg LY544344 b.i.d., 16 mg LY544344 b.i.d., or placebo in a 1 : 1 : 1 ratio. LY544344 or placebo was provided in identical opaque white capsules packaged in blister cards. To balance randomization groups for baseline anxiety severity levels, patients were stratified based on baseline HAMA scores p23 or 423. Upon completion of the 8-week acute treatment phase or discontinuation of double-blind therapy, patients were requested to return for a follow-up visit to collect adverse event information 2 weeks after therapy discontinuation. Study drug was not tapered at the end of treatment.
Concomitant psychotropic medications were not allowed with the exception of zaleplon (up to 10 mg), zolpidem (up to 10 mg), zopiclone (up to 7.5 mg), or chloral hydrate (up to 1000 mg) at bedtime up to three times per week, if needed, for sleep. Patients receiving psychotherapy were permitted to enroll if therapy began at least 3 months before enrollment in the study, and neither introduction nor change in intensity or frequency of psychotherapy was permitted during the course of the study.
Patient Population
Patients had DSM-IV-defined GAD as assessed by a thorough psychiatric examination, including an interview with the Mini International Neuropsychiatric Interview (Sheehan et al, 1998) and review of medical records and collateral information, where available. Patients were men or women at least 18 years of age who presented at screening with a Hospital Anxiety and Depression Scale (HADS) (Zigmond and Snaith, 1983) anxiety subscale score of X10, as well as a Clinical Global Impressions of Severity score X4 (CGI-S; Guy, 1976) , a Covi anxiety scale score X9 (Lipman, 1982) , and a Raskin depression scale score p7 with no item X4 (Raskin et al, 1969) . No minimum HAMA score was required for inclusion into the study, to minimize any potential distortions in primary efficacy measure (HAMA) baseline scores (Moore et al, 2006) . Patients with other current axis I disorders, with the exception of specific phobia, or lifetime history of psychotic disorders, bipolar disorder, obsessive-compulsive disorder, or factitious disorders were excluded. Patients were also excluded if their anxiety symptoms, in the investigator's opinion, were due to an underlying acute or chronic general medical condition or substance use/withdrawal, if they had an unstable serious illness (including cardiac, hepatic, renal, respiratory, endocrinologic, neurologic, or hematologic disease), or abnormal thyroid function, or had used a drug with psychotropic effects, other than the sedative hypnotics specified above, within 10 days before randomization. 
Assessments
The primary efficacy assessment used in this study was the HAMA total score. Other a priori efficacy assessments included the CGI-S; the Clinical Global ImpressionImprovement (CGI-I; Guy, 1976) ; the Montgomery Asberg Depression Rating Scale (MADRS; Montgomery and Asberg, 1979) , and HADS. Treatment response was predefined as a CGI-I scale score of 1 (very much improved), or 2 (much improved), or a decrease from baseline in HAMA total score by at least 50%. Remission was defined as a HAMA total score of 7 or less at the last visit in the acute treatment period (Ballenger, 2001 ). An investigator meeting was held before initiation of the study to instruct investigators and study raters on study procedures and review the use of relevant clinical rating scales. Prospective study raters were required to have previous clinical and research experience, to view a videotape of a clinical interview and provide HAMA individual item and total scores that were consistent with the scores provided by expert raters for that interview, and to conduct a brief mock interview in the presence of sponsor clinical personnel where items of the HAMA were rated. These procedures were conducted to ensure adequacy and consistency of clinical ratings across investigator sites. Safety and tolerability were assessed via the collection of spontaneously elicited treatment-emergent adverse events at each visit, including serious adverse events and events leading to study discontinuation. Standard laboratory tests, including blood chemistry and hematology, were performed at screening and after 4 and 8 weeks of randomized therapy. Plasma concentration of LY544344 and LY354740 were assessed 2, 4, and 8 weeks after randomization, and electrocardiograms were performed at baseline and end point, or at the time of early discontinuation. Vital signs, including sitting blood pressure (systolic and diastolic), heart rate, and weight were also collected at all visits. A comprehensive physical examination was performed at screening and upon discontinuation of study drug treatment.
Statistical Methods
The a priori specified primary efficacy analysis was the comparison of LY544344 and placebo in mean change from baseline to last observation in the HAMA total score for the double-blind treatment phase. A linear combination of 16 mg b.i.d.Àplacebo) in mean change from baseline to last observation in the HAMA total score during the doubleblind treatment phase. The linear combination was tested using a contrast hypothesis statement within the analysis of covariance (ANCOVA) model. The contrast compares the regression coefficients of the LY544344 treatment groups against placebo (Ho: (B LY16 + B LY8 )/2 ¼ B P ). An ANCOVA model was used containing terms for treatment, investigator, and category of anxiety severity, with baseline HAMA total score as a covariate. If the primary hypothesis was statistically significant at the 0.05, two-sided level, the LY544344 8 mg b.i.d. vs placebo and the LY544344 16 mg b.i.d. vs placebo were tested at the 0.05 significance level without any penalty for multiple comparisons.
As this study was testing novel inclusion criteria where no minimum HAMA total score for enrollment into the study was required, to ensure that the patients included in the primary efficacy analysis would have adequate baseline severity a qualified population was prespecified: only those patients having a baseline HAMA total score X18 and at least one post-baseline measure were included in the efficacy analyses. The criteria for qualification were blinded from investigators; patients not meeting these criteria were allowed to continue in the study. The study intended to randomize a total of approximately 672 patients. It was expected that approximately 185 patients per treatment arm would meet the a priori criteria for the qualified patient population. This sample size was expected to provide 80% power to detect a treatment effect size of 0.3 based upon a two-sided 0.05 t-test. If the primary hypothesis was statistically significant at the 0.05, two-sided level, pairwise comparisons with placebo were tested at the 0.05 significance level without penalty for multiple comparisons. Comparisons between treatment groups were assessed using an ANCOVA model containing terms for treatment, investigator, and baseline anxiety strata. The effect size for change in HAMA total score (a continuous variable) was created from Glass estimation (Hedges and Olkin, 1985) . The effect size for change was calculated as the difference in mean change between the placebo group and the particular LY544344 dose group (a positive difference shows drug superiority) in the same study divided by the pooled sample standard deviation of the two treatment groups. Using the large sample asymptotic distribution property and under Ho, the effect size was asymptotically normally distributed with mean zero and the estimated variance of (N d 
where N d and N c denote the sample size for LY544344 and placebo treatment groups, respectively, and g stands for the estimated effect size. An estimated 95% CI for the effect size was created utilizing these estimators and the critical values from a standard normal distribution. To further assess treatment effects over time, an observed case analysis of HAMA total score mean change from baseline to each visit using the model described above was also performed. CGI-I scores were analyzed using an analysis of variance (ANOVA) model containing terms for treatment, investigator, and baseline anxiety strata. Response and remission rates were analyzed using a Cochran-Mantel-Haenszel test for general association controlling for investigator and baseline anxiety strata.
All safety analyses were conducted on an intent-to-treat (ITT) basis. An ITT analysis is an analysis of data by the groups to which patients are assigned by random allocation, even if the patient does not take the assigned treatment, does not receive the correct treatment, or otherwise does not follow the protocol. Continuous safety variables were analyzed using an ANOVA model with treatment and investigator terms. Categorical safety variables were analyzed using Fisher's exact test. Treatment group differences were evaluated based on a two-sided, 0.05 significance level.
For the double-blind acute treatment phase analyses, baseline was defined as the last non-missing measurement before randomization. The last observation during the double-blind acute treatment phase was the last non-missing measurement obtained during the acute therapy phase. 
RESULTS
Patient Demographics and Disposition
Owing to findings of convulsions in preclinical studies with LY544344, the study was stopped and active patients were discontinued before the full prespecified sample (B672 patients) was enrolled. At the time of study discontinuation, 148 patients had provided informed consent, with 111 patients randomized. Of 108 (97.3%) patients meeting criteria for qualified patients, 103 (92.8%) had baseline and at least one post-baseline observation. Sixty-eight patients were discontinued due to premature study termination, six due to adverse events, six due to lack of efficacy, and two due to lost to follow-up; there were no meaningful differences in patient disposition across treatment groups. Only 29 patients (26.1%) completed the double-blind treatment phase and entered the single-blind placebo, drug discontinuation assessment phase. Clinical and demographic characteristics of the study sample are presented in Table 1 . Number of patients remaining in the study by treatment and week of therapy are provided in Figure 1 ; there were no significant differences among treatment groups on baseline characteristics or disposition.
Efficacy Results
The efficacy results are based upon the qualified subset; results for the entire randomized sample did not differ significantly from the results in the qualified subset. In the observed case analysis of the HAMA total score, the LY544344 16 mg b.i.d.-treated groups experienced a significantly greater improvement from baseline than the placebo-treated patients at week 8 (Figure 1 ). The LY544344 8 mg b.i.d. treatment group showed numerically greater mean improvement than the placebo treatment group at week 8, but this difference was also not statistically significant (Figure 1 
Adverse Events
The most frequently reported treatment-emergent adverse event among randomized patients in all three treatment groups was nausea ( 
LY354740 Plasma Concentrations
Plasma samples for determination of LY544344 and LY354740 plasma concentrations were obtained approximately 2, 4, and 8 weeks after initiation of randomized treatment (Table 3) There were no significant differences in the incidence of adverse events across treatment groups. mGlu2/3 agonist in GAD E Dunayevich et al significant differences in several secondary efficacy measures used, such as the HADS, MADRS, or the CGI-S scores for both LY544344 groups. Lack of significant effects on these measures may be due in part to lack of statistical power to detect differences among treatment groups stemming from the diminished sample size. Lack of treatment effect on depressive symptoms may also be due to inclusion criteria limiting depression severity in this sample, as evidenced by the low baseline scores on the MADRS and HADS depression subscale. Alternative explanations may also include therapeutic effects being more apparent in clinician-(eg, HAM-A, CGI-I) as opposed to patient-rated scales (eg, HADS anxiety subscale), or lack of antidepressant effects from mGlu2/3 agonists. The doubleblind design and the benign safety and tolerability profile of LY544344 make it unlikely that awareness of treatment assignment by investigators would have biased efficacy ratings. However, as raters were not blind to patientreported adverse events and because a numerically higher rate of nausea was observed in the LY544344 treatment groups, some degree of unblinding to treatment assignment cannot be ruled out. Limited effects in patient-rated and depressive symptom measures are consistent with LWAY findings (Michelson et al, 2005) . Adverse events were infrequent and mild among the LY544344 and placebo groups, and no serious adverse events were noted. Rates of discontinuation due to adverse events were small, indicating that LY544344 was well tolerated in this population. No clinically significant observations were made regarding changes in vital signs, EKGs, or laboratory assessments, including blood chemistries and hematology. There were no reports of convulsions or other neurobehavioral adverse events. Plasma concentrations of LY354740 were comparable to those previously associated with efficacy in GAD (data on file, Eli Lilly and Co.), confirming the utility of using a dipeptide analog to increase the oral bioavailability (by way of peptide transporters) of otherwise poorly absorbed amino-acid analogs such as LY354740 (Bueno et al, 2005; Rorick-Kehn et al, 2006) . The use of the prodrug LY544344 is associated with increased oral bioavailability and decreased variability of active moiety (LY354740) in plasma concentration. This leads to more predictable clinical effects at a given dose and lower manufacturing costs relative to the poorly bioavailable parent drug LY354740.
The efficacy, safety, and tolerability results of this study add to the emerging field of data suggesting the important role of glutamatergic modulation of anxiety and related symptoms (Swanson et al, 2005) . Other agents affecting glutamate neurotransmission, such as ketamine, lamotrigine, and riluzole have been available for clinical use for some time (for review, see Zarate et al, 2002) . Riluzole, an inhibitor of glutamate release indicated for the treatment of amyotrophic lateral sclerosis, was found efficacious in an open-label GAD trial (Mathew et al, 2005) . Of note, LY354740 and its prodrug LY544344 are the first agents to target specific G-protein-linked glutamate receptors that modulate glutamatergic transmission and to be clinically investigated (Swanson et al, 2005) . LY354740 is nanomolar (Schoepp, 2001; Schoepp et al, 2003) . It is established that the activation of mGlu2/3 receptors leads to reductions in the evoked release of glutamate and concomitant reduction on post-synaptic glutamate-mediated excitations (Schoepp, 2001) . Localization studies with mGlu2 or mGlu2/3 selective antibodies indicate that the mGlu2 receptors are located primarily at presynaptic sites, but they are external to the synaptic junctions (Cartmell and Schoepp, 2000) . Thus, mGlu2 receptors likely monitor glutamate, which escapes the synapse upon excessive release of neurotransmitter (eg, high-frequency stimulations) or when uptake processes in glial and/or neurons that clear synaptic glutamate have been compromised. Thus, mGlu2 receptors have an important regulatory role in preventing pathological glutamate excitation from occurring, but play less of a role in physiological excitatory transmission per se. mGlu2 and/or mGlu3 receptors are also present post-synaptically, where they hyperpolarize cells thus decreasing excitability (Tamaru et al, 2001 ). mGlu3 receptors have been identified on glial cells where their function is less understood (Schoepp, 2001) . In brain synapses involved in fear and anxiety responses, mGlu2/3 receptor agonists have been shown to decrease presynaptic glutamate release and induce postsynaptic hyperpolarization, thus modulating limbic neuronal excitability. The basolateral and central nucleus of the amygdala, medial prefrontal cortex, and the lateral and medial perforant paths of the hippocampus are some of the brain areas where LY354740 can inhibit glutamate-evoked synaptic excitatory responses (Schoepp et al, 2003) . These areas have been implicated in modulation of anxiety/fear in animals and humans (Pratt, 1992) and the acquisition and expression of fear/anxiety responses (Davis et al, 1994) . In the amygdala, cFOS studies also suggest that LY354740 prevents disinhibition of circuits that drive fear responses by modulating GABAergic transmission (Linden et al, 2004) . Modulation of glutamate-or GABA-mediated excitability in limbic circuits by LY354740 likely represents the key mechanism(s) of action that lead to the anxiolytic effects observed with these agents in preclinical anxiety models as well as human studies (Schoepp et al, 2003) . The only known human data with mGlu2/3 agonists to date have been limited to studies with LY354740 or LY544344. In addition to the previously discussed GAD studies, a cholecystokinin tetrapeptide challenge to induce anxiety in healthy volunteers demonstrated equivocal effects of LY544344 80 mg b.i.d. (Kellner et al, 2005) . A double-blind clinical trial with LY354740 was conducted in panic disorder patients. The study found treatment with LY354740 200-400 mg/day no more efficacious than treatment with placebo (Bergink and Westenberg, 2005 and data on file, Eli Lilly and Co.), in opposition to positive LY354740 efficacy findings in a human model of panic anxiety (Schoepp et al, 2003) . The reasons for the lack of efficacy in panic disorder are not clear; higher doses or LY354740 exposures that can be achieved with other mGlu2/3 agonists with better bioavailability, such as LY544344, may be needed to treat conditions other than GAD. Few studies have been performed to assess the efficacy of LY354740 or LY544344 in conditions other than GAD, and no LY544344 human studies have been conducted to date in panic or major depressive disorder. Additional clinical studies will be necessary to further outline the spectrum of disorders in which mGlu2/3 agonist agents may be efficacious.
While the mechanism underlying the preclinical findings of convulsions remains unknown, it is unclear to what extent these findings are relevant to humans, as no convulsions were observed in humans receiving LY354740 for more than 1 year, or LY544344 for up to 8 weeks. Convulsions were observed after repeated dosing in an 8-month dog study at LY544344 doses as low as 60 mg/kg, and in 2-year rat and mouse studies at doses as low as 70 and 150 mg/kg, respectively. The observation of convulsions in preclinical species and the potential for increased convulsion risk in humans led to discontinuation of this study. The clinical significance of animal convulsions remains unknown. To establish the potential clinical utility of mGlu2/3 receptor agonist agents, further evaluation of their preclinical and clinical safety and tolerability will be required.
In summary, results of this study appear to confirm previous findings indicating that agonism at mGlu2/3 receptors may be associated with anxiolytic effects in humans. The potential therapeutic role of mGlu2/3 agonists in the treatment of anxiety disorders awaits further preclinical and more definitive clinical evaluation.
